Clinical Trial Update: Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a phase 1/2 study evaluating gene-modified donor T-cells after TCR alpha beta–negative depleted stem cell transplant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Anemia Aplastic
• Cytopenia
• Hemoglobinopathy in Children
• Immune Deficiency Disease
• Leukemia Acute Myeloid
• Lymphoma Non-hodgkin
• Myelodysplastic Syndromes
• Osteopetrosis

Drugs mentioned

• Gene Modified Donor T-cells after TCR Alpha Beta Positive Depleted Stem Cell Transplant

Snippet

Sponsor: Bellicum Pharmaceuticals | Conditions: Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING